4.5 Article

High performance liquid chromatography-tandem mass spectrometry for the determination of bile acid concentrations in human plasma

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.jchromb.2009.11.019

关键词

Bile acids; Liquid chromatography-mass spectrometry; Healthy subjects; Bile acid-free plasma; Bile acid stability

资金

  1. Sigrid Juselius Foundation (Helsinki, Finland)
  2. Helsinki University Central Hospital Research Fund (Helsinki, Finland)

向作者/读者索取更多资源

We report a sensitive and robust method to determine cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithocholic acid (LCA), ursodeoxycholic acid (UDCA), and their taurine- and glycine-conjugate concentrations in human plasma using liquid chromatography-tandem mass spectrometry. Activated charcoal was utilized to prepare bile acid-free plasma, which served as the biological matrix for the preparation of standard and quality control samples. Plasma sample preparation involved solid-phase extraction. A total of 16 bile acids and 5 internal standards were separated on a reverse column by gradient elution and detected by tandem mass spectrometry in negative ion mode. The calibration Curve was linear for all the bile acids over a range of 0.005-5 mu mol/L. The extraction recoveries for all the analytes fell in the range of 88-101%. Intra-day and inter-day coefficients of variation were all below 10%. A stability test showed that all the bile acids were stable in plasma for at least 6 h at room temperature, at least three freeze-thaw cycles, in the -70 degrees C or -20 degrees C freezer for 2 months, and also in the reconstitution solution at 8 degrees C for 48 h. Comparison of the matrix effect of bile acid-free plasma with that of real plasma indicated that the charcoal purification procedure did not affect the properties of charcoal-purified plasma as calibration matrix. This method has been used to determine the bile acid concentrations in more than 300 plasma samples from healthy individuals. In conclusion, this method is Suitable for the simultaneous quantification of individual bile acids in human plasma. (C) 2009 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

PharmVar GeneFocus: SLCO1B1

Laura B. Ramsey, Li Gong, Seung-Been Lee, Jonathan B. Wagner, Xujia Zhou, Katrin Sangkuhl, Solomon M. Adams, Robert J. Straka, Philip E. Empey, Erin C. Boone, Teri E. Klein, Mikko Niemi, Andrea Gaedigk

Summary: PharmVar provides star allele nomenclature for the SLCO1B1 gene, which plays an important role in drug transport and metabolism. The standardized nomenclature has been adopted by CPIC and incorporated into guidelines.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4 and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A in vitro

Marie-Noeurolle Paludetto, Mika Kurkela, Helina Kahma, Janne T. Backman, Mikko Niemi, Anne M. Filppula

Summary: This study aimed to explore the cytochrome P450 metabolic and inhibitory profile of hydroxychloroquine (HCQ). The results showed that CYP3A4, CYP2D6, and CYP2C8 are the key enzymes involved in HCQ metabolism. HCQ and its metabolites showed reversible inhibition of CYP2D6 and time-dependent inhibition of CYP3A. Rating: 8/10.

DRUG METABOLISM AND DISPOSITION (2023)

Article Pharmacology & Pharmacy

Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs

Feng Deng, Noora Sjostedt, Mariangela Santo, Mikko Neuvonen, Mikko Niemi, Heidi Kidron

Summary: Drug-drug interactions (DDIs) can have a significant impact on the safety of medication use. This study aimed to identify inhibitors of the breast cancer resistance protein (BCRP) among a library of commonly used drugs and anticancer drugs. 75 drugs were found to strongly inhibit BCRP, with vemurafenib, dabigatran etexilate, and everolimus being the most potent inhibitors. These findings suggest that clinical studies are needed to examine whether these drugs cause BCRP-mediated DDIs in humans.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)

Article Biochemistry & Molecular Biology

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling

Xiwei Ji, Xiangrui Meng, Qingfeng He, Xiaoqiang Xiang, Yufei Shi, Xiao Zhu

Summary: This study investigated the antitumor effects of foretinib on triple-negative breast cancer cells and its pharmacokinetic characteristics. The results showed that foretinib inhibited tumor growth in a dose-dependent manner and suppressed the expression of p-MET and HGF in both cells and tumors, suggesting that the decrease of p-MET and HGF may play a crucial role in the anti-breast cancer properties of foretinib.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Public, Environmental & Occupational Health

Pharmacogenetics of warfarin and healthcare costs - Real-world data analysis

Jaakko Lahteenmaki, Anna-Leena Vuorinen, Mika Lehto, Mikko Niemi, Markus M. Forsberg

Summary: The study aimed to investigate the differences in healthcare costs between genetically normal and genetically sensitive warfarin responder groups. The findings showed that the sensitive responder group had higher bleeding-related hospital costs and INR test costs, but lower medication costs. This suggests that genotype-guided warfarin dosing may help reduce the risk of bleeding.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2023)

Article Pharmacology & Pharmacy

Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer

Feng Deng, Maren Laasik, Liina Salminen, Lauri Lapatto, Kaisa Huhtinen, Yilin Li, Sampsa Hautaniemi, Johanna Hynninen, Mikko Niemi, Rainer Lehtonen

Summary: The study identified genetic variations in SLCO1B3, LIG3, GSTP1, ABCB1, and OPRM1 associated with risk of adverse effects, treatment response, and prognosis in patients receiving carboplatin-paclitaxel therapy for ovarian cancer.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Article Pharmacology & Pharmacy

CYP3A422 may increase bleeding risk in ticagrelor users

Hilkka Liedes, Juha Pajula, Anna-Leena Vuorinen, Francesco De Pretis, Mark van Gils, Kari Harno, Mika Lehto, Mikko Niemi, Jaakko Lahteenmaki

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Article Pharmacology & Pharmacy

Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction?

Minna Lehtisalo, Wilma Kiander, Anne M. M. Filppula, Feng Deng, Heidi Kidron, Mari Korhonen, Johanna Sinkko, Kimmo Koivula, Mikko Niemi

Summary: We report 3 cases of rhabdomyolysis diagnosed in patients 1-6 months after the concurrent use of rosuvastatin and ticagrelor. A review of the literature and the Food and Drug Administration adverse event reporting system revealed more than 40 reports of rhabdomyolysis during concomitant ticagrelor and rosuvastatin, including 3 fatal cases. In vitro studies showed that ticagrelor inhibits the transport of rosuvastatin by breast cancer resistance protein, organic anion transporting polypeptide (OATP) 1B1, 1B3, and 2B1, with inhibitory concentrations ranging from 0.36 to 7.5 μM. Our findings suggest that the concomitant use of ticagrelor and rosuvastatin may lead to an increased risk of rosuvastatin-induced rhabdomyolysis due to the inhibition of rosuvastatin transport. Further research is needed to investigate the pharmacokinetic interaction between ticagrelor and rosuvastatin in humans.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)

Article Medicine, Research & Experimental

Functional Characterization of Six SLCO1B1 (OATP1B1) Variants Observed in Finnish Individuals with a Psychotic Disorder

Katja Hakkinen, Wilma Kiander, Heidi Kidron, Markku Lahteenvuo, Lea Urpa, Jonne Lintunen, Kati-Sisko Vellonen, Seppo Auriola, Minna Holm, Kaisla Lahdensuo, Olli Kampman, Erkki Isometsa, Tuula Kieseppa, Jouko Lonnqvist, Jaana Suvisaari, Jarmo Hietala, Jari Tiihonen, Aarno Palotie, Ari V. Ahola-Olli, Mikko Niemi

Summary: Six rare SLCO1B1 single nucleotide variants (SNVs) were identified in Finnish individuals with a psychotic disorder, which may affect the expression and functionality of the OATP1B1 protein. Functional studies showed that one of these SNVs (c.629G>T) resulted in the loss of OATP1B1 function and decreased membrane protein expression.

MOLECULAR PHARMACEUTICS (2023)

Article Medicine, Research & Experimental

Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides

Christine C. Orozco, Mikko Neuvonen, Yi-An Bi, Matthew A. Cerny, Sumathy Mathialagan, Laurie Tylaska, Brian Rago, Chester Costales, Amanda King-Ahmad, Mikko Niemi, A. David Rodrigues

Summary: This study found that sulfated bile acids (BA-S) can potentially serve as clinical biomarkers for OATP1B1/3. The BA-S substrates were observed in OATP1B1, OATP1B3, and NTCP transfected into human embryonic kidney 293 cells, with minimal uptake in other solute carriers (SLCs). Inhibition of BA-S uptake in human hepatocytes was greater with rifampicin (OATP1B1/3 selective inhibitor) than other inhibitors.

MOLECULAR PHARMACEUTICS (2023)

Article Pharmacology & Pharmacy

Inhibition of efflux transporters by poly ADP-ribose polymerase inhibitors

Feng Deng, Johanna Sistonen, Mikko Neuvonen, Mikko Niemi

Summary: This study evaluated the potential interactions between PARP inhibitors and statins, and found that PARP inhibitors can inhibit certain transporter proteins, potentially increasing the exposure of statins. However, the clinical significance of these interactions is minimal, although they may increase the risk of adverse effects when combined with other predisposing factors.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2023)

Article Medicine, Research & Experimental

CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel

Markus Ramste, Markus Ritvos, Sergei Hayrynen, Johanna I. Kiiski, Mikko Niemi, Juha Sinisalo

Summary: The aim of this study was to investigate the influence of CYP2C19 loss-of-function variants and CYP2C19 inhibitors, such as omeprazole or esomeprazole, on the incidence of cardiovascular events in patients using clopidogrel. The study found that carriers of CYP2C19 loss-of-function alleles had a higher frequency of cardiovascular events compared to non-carriers. Additionally, the use of omeprazole or esomeprazole was similar between carriers and non-carriers. These findings suggest that both genetics and concomitant medication should be considered for optimal patient care.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2023)

Article Biotechnology & Applied Microbiology

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants

K. Ivar Lonnberg, Aleksi Tornio, Paivi Hirvensalo, Jenni Keskitalo, Anna-Liina Mustaniemi, Johanna I. Kiiski, Anne M. Filppula, Mikko Niemi

Summary: This study investigated the associations between SLCO1B1 c.521T>C and the intolerance to atorvastatin, fluvastatin, pravastatin, rosuvastatin, or simvastatin, between ABCG2 c.421C>A and the intolerance to atorvastatin, fluvastatin, or rosuvastatin, and between CYP2C9*2 and *3 alleles and the intolerance to fluvastatin. The results confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance and suggested the feasibility for larger future studies.

PHARMACOGENETICS AND GENOMICS (2023)

Article Pharmacology & Pharmacy

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir

Wenyu Yang, Wenyao Mak, Amanda Gwee, Meng Gu, Yue Wu, Yufei Shi, Qingfeng He, Xiaoqiang Xiang, Bing Han, Xiao Zhu

Summary: This study aimed to establish a parametric model repository of ganciclovir and valganciclovir by summarizing existing population pharmacokinetic information and analyzing the sources of variability. The results showed that dosing regimens should be adjusted according to body size and renal function.

PHARMACEUTICS (2023)

Article Peripheral Vascular Disease

The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction

Lotta Ulander, Piia Simonen, Heli Tolppanen, Otto Hartman, Tuomas T. Rissanen, Kari K. Eklund, Marita Kalaoja, Mika Kurkela, Mikko Neuvonen, Mikko Niemi, Janne T. Backman, Helena Gylling, Juha Sinisalo

Summary: This study evaluated the effects of hydroxychloroquine on serum and lipoprotein lipids and biomarkers of cholesterol synthesis and absorption in myocardial infarction patients treated with a high-dose statin. The results showed that hydroxychloroquine had no additional effect on cholesterol concentration or absorption, but it did interfere with lanosterol synthesis and temporarily halted the increase of the desmosterol ratio, suggesting an interference with the cholesterol synthesis pathway.

ATHEROSCLEROSIS PLUS (2023)

暂无数据